- Details
- Aránzazu González del Alba discusses the SOGUG’s multifaceted mission. SOGUG, primarily known for its annual scientific symposium, focuses on multidisciplinary work in genitourinary cancer, involving specialists like urologists, pathologists, and radiologists. This year, the symposium emphasizes patient experiences, inviting them to share their stories and stay informed about advancements in genit...
|
- Details
- Charles Ryan interviews Ignacio Peláez to discuss the evolving landscape of second-line treatments for kidney cancer, emphasizing the dependency of these treatments on first-line therapy choices. Dr. Peláez explains that the selection of second-line treatments is influenced by the initial therapy, which has undergone a therapeutic revolution from TKI monotherapy to combinations of immunotherapy an...
|
- Details
- Elena Castro joins Alicia Morgans in a discussion on the clinical trial landscape for metastatic castration-resistant prostate cancer. When seeing a patient, Elena considers prior therapies and genetic testing, noting BRCA1 and BRCA2 alterations being investigated earlier provide an opportunity to treat patients with different PARP inhibitors. Drs. Morgans and Castro highlight the use of radiophar...
|
- Details
- Tiago Padua presents an overview of ongoing clinical trials in rare GU tumors, including adrenal tumors, testicular cancer, and penile cancer, at a medical conference. He emphasizes the challenges of treating these tumors due to lack of guidelines, low recruitment, limited funds, and underscores the importance of international collaboration. Details are provided about several trials, such as a Pha...
|
- Details
- Alicia Morgans interviews Toni Choueiri to discuss key topics related to kidney cancer. They delve into strategies for treating metastatic kidney cancer, focusing on combined and sequential drug approaches. Dr. Choueiri elaborates on failures and successes, particularly regarding the use of three drugs simultaneously and the importance of managing toxicity. They also discuss treatment for patients...
|
- Details
- Karim Fizazi discusses the substantial progress made in treating metastatic castration-sensitive prostate cancer. In their conversation, Dr. Fizazi emphasizes the importance of understanding different patient scenarios based on volume and the timing of the metastasis, highlighting the distinctions between de novo metastatic disease and relapse after local treatment. He breaks down four scenarios t...
|
- Details
- Jeffrey Ross speaks about the evolution and application of liquid biopsies in cancer treatment, including in cases of advanced metastatic breast cancer and prostate cancer. Drawing from his experience with circulating cancer cells, he details the development of circulating DNA and emphasizes the importance of precision medicine and personalized care. He contrasts liquid biopsies with tissue biopsi...
|
- Details
- Adam ElNaggar presents details about Signatera, a personalized tumor-informed molecular residual disease test. The focus of his talk includes explaining the prognostic and predictive value of circulating tumor DNA (ctDNA) and its role in clinical trial design. Dr. ElNaggar emphasizes that Signatera is specific to an individual's tumor, and its methodology involves whole exome sequencing of both tu...
|
- Details
- Alicia Morgans interviews Maria De Santis about the use of immunotherapy in the perioperative space for treating urothelial carcinoma. The focus lies on neoadjuvant approaches, especially for patients ineligible for cisplatin-based chemotherapy. Dr. De Santis notes the importance of systemic therapy for treating early micrometastatic disease, offering hope for survival benefits. She highlights ong...
|
- Details
- Alicia Morgans speaks with Maria De Santis about the progressive developments in treating metastatic urothelial carcinoma. Dr. De Santis expresses excitement about the introduction of avelumab maintenance therapy, a new standard of care following platinum-based chemotherapy, which marks the first survival advantage in this field in three decades. She discusses the efficacy of enfortumab vedotin, a...
|
